The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan: randomized crossover controlled trial The effect of dapagliflozinin autosomal dominant polycystic kidney disease patients using tolvaptan: ...
The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan: randomized crossover controlled trial - The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan The effect of dapagliflozinin autosomal dominant polycystic kidney disease patients using tolvaptan: ...
Dapagliflozin 10mg/day for 6 months No treatment for 6 months
Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine
Department of Nephrology, International University of Health and Welfare School of MedicineDivision of Nephrology, Japanese Red Cross Medical Center Department of Nephrology, International University of Health and Welfare School of MedicineDivision ...